Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation?

Antioxid Redox Signal. 2010 Jun 1;12(11):1333-7. doi: 10.1089/ars.2009.2956.

Abstract

Hydrogen sulfide (H(2)S) is emerging as a physiological neuromodulator as well as a smooth muscle relaxant. We submit the first evidence that blood H(2)S levels are significantly lower in fasting blood obtained from type 2 diabetes patients compared with age-matched healthy subjects, and in streptozotocin-treated diabetic rats compared with control Sprague-Dawley rats. We further observed that supplementation with H(2)S or an endogenous precursor of H(2)S (l-cysteine) in culture medium prevents IL-8 and MCP-1 secretion in high-glucose-treated human U937 monocytes. These first observations led to the hypothesis that lower blood H(2)S levels may contribute to the vascular inflammation seen in diabetes.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Blood Vessels / drug effects*
  • Blood Vessels / pathology*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / chemically induced*
  • Diabetes Mellitus, Type 2 / immunology
  • Glucose / pharmacology
  • Humans
  • Hydrogen Sulfide / blood*
  • Hydrogen Sulfide / pharmacology
  • Inflammation / chemically induced*
  • Inflammation / pathology
  • Male
  • Middle Aged
  • Monocytes / cytology
  • Monocytes / drug effects
  • Monocytes / immunology
  • Rats
  • Rats, Sprague-Dawley
  • Streptozocin / adverse effects

Substances

  • Streptozocin
  • Glucose
  • Hydrogen Sulfide